Five Prime: Glaxo Exercises Option for Rights to Muscle-Disease Products
BY Dow Jones & Company, Inc. — 9:55 AM ET 09/16/2014
..... exercised its option for an exclusive global license to products related to an undisclosed muscle-disease target discovered by the clinical-stage biotechnology company.
Five Prime shares were recently trading at $12.07, up 4.9%.
Five Prime will receive a payment of $1.5 million in connection with the option exercise and is eligible for as much as $122.5 million in milestone payments.
Five Prime and Glaxo began a collaboration in 2010 to discover and develop drug targets for skeletal muscle diseases using Five Prime's platform.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.